This proposal represents a request for continued funding of the NIH-sponsored Clinical Pharmacology Fellowship Training Program at the Mayo Clinic-Mayo Clinic College of Medicine-Mayo Medical School. The foundation for this program is strong research training in state-of-the-art biomedical techniques as applied to human-drug interactions. The Mayo Clinical Pharmacology training experience includes a curriculum that systematically exposes Trainees to critical aspects of the science that underlies Clinical Pharmacology. At the heart of the training is an outstanding individual research experience within a supportive mentoring environment. Clinical Pharmacology is a "bridge discipline" devoted to the study of the interaction between drugs and biological systems. However, within the context of the ongoing "revolution" that is occurring in biomedical science, a revolution that promises to transform medical practice, Clinical Pharmacology lies at the confluence of molecular pharmacology, genomics, proteomics, bioinformatics and rational therapeutics-with an ultimate goal of truly "individualized" drug therapy. Specifically, Clinical Pharmacology seeks to enhance our understanding of the molecular basis for drug response and the application of that information at the translational interface to make it possible to tailor drug therapy to both he underlying disease process and the unique characteristics of each individual patient. Our ability to take advantage of the opportunity represented by the dramatic advances that are occurring in biomedical science to achieve those goals will require that we train a new generation of Clinical Pharmacologists in "Systems Clinical Pharmacology". Large, comprehensive, integrated academic medical centers like the Mayo Clinic are ideally positioned to train this new generation of Clinical Pharmacologists. Mayo is able to do that because of its long history of the integration of basic and clinical medical research, because of a tradition of continuous contribution to the discipline of Clinical Pharmacology and because the Mayo Clinical Pharmacology Training Program has had decades of experience in successfully recruiting and training both physician scientists and laboratory-based translational scientists in Clinical Pharmacology. During the next funding cycle, the Mayo Clinical Pharmacology Fellowship Training Program will continue to emphasize strong laboratory-based research training in a supportive mentored environment joined with systematic exposure to developments in clinical science, with an emphasis on the rapidly evolving nature of biomedical science-all directed toward the goal of preparing each Fellow enrolled in the Program to become a future leader in Clinical Pharmacology.

Public Health Relevance

This proposal is a request for continued funding of the NIH-sponsored Clinical Pharmacology Fellowship Training Program at the Mayo Clinic. Clinical Pharmacology is a bridge discipline that lies at the confluence of molecular pharmacology, genomics, bioinformatics and rational therapeutics-with the ultimate goal of truly individualized drug therapy.

Agency
National Institute of Health (NIH)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM008685-17
Application #
8689069
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Okita, Richard T
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Eugene, Andy R; Masiak, Jolanta (2016) Identifying Treatment Response of Sertraline in a Teenager with Selective Mutism using Electrophysiological Neuroimaging. Int J Clin Pharmacol Toxicol 5:216-219
Elraiyah, Tarig; Jerde, Calvin R; Shrestha, Shikshya et al. (2016) Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an East African population. Clin Pharmacol Ther :
Pratz, Keith W; Koh, Brian D; Patel, Anand G et al. (2016) Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. Clin Cancer Res 22:3894-902
Eugene, Andy R (2016) Metoprolol Dose Equivalence in Adult Men and Women Based on Gender Differences: Pharmacokinetic Modeling and Simulations. Med Sci (Basel) 4:
Eugene, Andy R (2016) Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations. Int J Clin Pharmacol Toxicol 5:209-215
Welch, Brian T; Petersen-Jones, Humphrey G; Eugene, Andy R et al. (2016) Impact of Sleep Disordered Breathing on Carotid Body Size. Respir Physiol Neurobiol :
Eugene, Andy R (2016) The influences of nitric oxide, epinephrine, and dopamine on vascular tone: dose-response modeling and simulations. Hosp Chron 11:1-8
Ding, H; Peterson, K L; Correia, C et al. (2016) Histone deacetylase inhibitors interrupt HSP90 RASGRP1 and HSP90 CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells. Leukemia :
Gupta, Shiv K; Kizilbash, Sani H; Carlson, Brett L et al. (2016) Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst 108:
Eugene, Andy R; Nicholson, Wayne T (2015) The Brain and Propranolol Pharmacokinetics in the Elderly. Brain (Bacau) 6:5-14

Showing the most recent 10 out of 49 publications